Safer – Smoke Master

Australia’s Backwards Nicotine Policy Leaves Cigarettes Legal and Safer Alternatives Restricted

admin — Sat, 29 Aug 2026 15:32:07 +0000

Australia has created one of the strangest nicotine markets in the developed world. Combustible cigarettes—the product responsible for the overwhelming majority of tobacco-related disease—remain legally available through ordinary retailers, while access to lower-risk alternatives has become progressively more difficult. The latest example is nicotine pouches.

From 24 July 2026, the Therapeutic Goods Administration removed the remaining consumer pathways for accessing nicotine pouches. Personal importation is no longer permitted, doctors cannot prescribe them through the Special Access or Authorised Prescriber schemes, and pharmacists cannot compound them. No nicotine pouch is currently included on the Australian Register of Therapeutic Goods, meaning there is effectively no lawful consumer supply.

The contrast could hardly be clearer: cigarettes remain on shelves while a tobacco-free product that produces neither smoke nor aerosol has effectively disappeared from the legal market. For tobacco harm reduction advocates, this represents Australia’s central policy problem—not insufficient regulation, but a risk hierarchy turned upside down.

Sweden shows what Australia is missing

Sweden is renowned for moving in the opposite direction. Instead of expecting every smoker to abandon nicotine entirely, it has allowed non-combustible alternatives to compete with cigarettes. Longstanding snus use has been joined by tobacco-free nicotine pouches, helping create a diverse market of products that avoid combustion.

Recent Swedish data put daily smoking at exceptionally low levels, while Smoke Free Sweden’s Power in a Pouch report argues that nicotine pouches have become particularly important among former smokers, especially women. Its survey found 26% of male and 28% of female ex-smokers identifying pouches as their most effective quitting aid. While a 2025 Cochrane review found no short-term serious harms in the small studies available and reductions in some biomarkers of tobacco-smoke exposure among smokers allocated to pouches.

Britain shows why consumer choice matters

The UK provides another useful example of a diversified harm-reduction market. Vaping remains the dominant alternative, supported by strong evidence for cessation. The latest Cochrane living review examined 104 studies involving more than 30,000 adults and concluded that nicotine vapes help more people quit smoking than conventional nicotine replacement therapy.

Nicotine pouches mostly attract smokers and recent ex-smokers. Action on Smoking and Health’s 2026 survey found current pouch use at 5.1% among smokers, 2.1% among ex-smokers and just 0.3% among never-smokers. Among people who had quit smoking during the previous year, pouch use reached 5.8%.

These figures suggest that the product currently appeals disproportionately to people with smoking histories rather than never-smokers. That matters because smokers tend to prefer vaping because it replicates inhalation and hand-to-mouth behaviour. But others clearly prefer an oral product that requires no device, produces no vapour and can be used discreetly. The more acceptable alternatives available, the greater the chance of finding something that can replace cigarettes for everyone.

Australia’s restrictions are feeding a massive black market

Australia is moving in the opposite direction while also experiencing an extraordinary shift toward illicit supply. Experimental modelling published by the Australian Bureau of Statistics estimates that total nicotine consumption increased by almost 40% between 2017 and 2025, despite population growth of only 14%. Over the same period, the estimated proportion supplied through illicit sources rose from 12% to 80%.

The ABS stresses that these estimates are not definite because wastewater can measure overall nicotine consumption but cannot determine which products produced it. Administrative and survey data must therefore be used to allocate consumption across cigarettes, vapes and other nicotine products.

Nevertheless, the underlying signal is difficult to ignore. Legal tobacco quantities fell to less than one-third of their 2017 level while total estimated nicotine consumption rose. The ABS concludes that substitution towards cheaper illicit products has more than offset declining legal consumption. Against that background, eliminating another lawful smoke-free option looks less like consumer protection and more like handing an established illicit market another product category.

New Zealand provides the most relevant comparison

Australia does not need to look as far as Sweden for an alternative regulatory model. Neighbouring New Zealand has historically regulated vaping as a legal consumer product rather than forcing consumers through Australia’s much narrower system. A 2025 study in Addiction compared smoking and vaping trends in the two countries between 2016 and 2023.

Daily smoking in New Zealand declined from 14.5% to 6.8%, compared with 12.2% to 8.3% in Australia. The researchers also found faster smoking reductions among lower socioeconomic groups and Indigenous populations in New Zealand.

The observational study cannot prove that vaping regulation alone caused this difference. But it provides a valuable natural comparison between neighbouring countries with similar conventional tobacco-control policies and sharply different approaches to safer nicotine alternatives. Importantly (and in this case mostly overlooked), consumer accounts indicate that Australia’s harsh restrictions on safer alternatives are where the problem lies.

Meanwhile, New Zealand itself does not yet operate an unrestricted legal nicotine-pouch market; oral nicotine products remain subject to specific medicines and psychoactive-substance rules. The stronger lesson from New Zealand is therefore about vaping: legal, regulated alternatives can coexist with faster declines in smoking.

Australia needs to put risk back at the centre

Australia’s problem is not that cigarettes are insufficiently regulated. It is that its nicotine framework repeatedly makes safer legal alternatives harder to obtain while illicit suppliers remain willing to provide whatever consumers want.

No one is implying that nicotine pouches should be sold freely and free of regulations. They should have enforceable standards covering nicotine content, ingredients, packaging and youth access. Manufacturers should be required to substantiate claims, and regulators should continue gathering long-term oral-health and epidemiological evidence. But none of that requires eliminating legal access.

A rational tobacco harm reduction strategy would put combustible cigarettes under the greatest regulatory and fiscal pressure, while creating controlled pathways for lower-risk products capable of replacing them. Australia has instead preserved the easiest legal route to the most dangerous product, restricted vaping and now effectively closed legal access to nicotine pouches—all while an enormous illicit nicotine economy has developed around those restrictions.

Sweden demonstrates the potential value of consumer choice. Britain shows different alternatives can appeal to different smokers. New Zealand shows that regulated vaping will lead to rapid declines in smoking. Australia’s approach remains the reverse: make safer products difficult to obtain, leave cigarettes readily available, then fight the black market that predictably fills the gap. If the objective is genuinely to reduce smoking-related disease, that hierarchy needs to be turned the right way up.

Australia Insists on Opting for Nicotine Prohibition, Despite Failing Miserably

Source link

GSTHR 2026: 200 Million Safer Nicotine Users Signal a Global Shift Away From Smoking

admin — Fri, 21 Aug 2026 13:09:24 +0000

The global nicotine market is undergoing a profound transformation, with millions of smokers moving away from combustible tobacco and towards safer nicotine products. Yet while consumers are increasingly embracing tobacco harm reduction, governments are often moving in the opposite direction.

The Global State of Tobacco Harm Reduction (GSTHR) 2026 Situation Report estimates that around 200 million people worldwide now use safer nicotine products (SNPs), including vapes, heated tobacco products, snus and nicotine pouches. That figure represents roughly one-fifth to one-quarter of the world’s approximately one billion smokers. The report’s central message is striking: the question may no longer be whether tobacco harm reduction will become a major force in nicotine use, but when policymakers will fully recognise it.

Where safer nicotine use goes up, smoking goes down

GSTHR analysis found that increasing use of safer nicotine products has coincided with declining smoking prevalence across 28 countries. In several nations—including Sweden, Norway, Iceland, New Zealand and the UK—use of safer nicotine products has already overtaken smoking.

Sweden, of course, still provides the most compelling example. High levels of snus and nicotine-pouch use have developed alongside exceptionally low smoking rates. GSTHR reports that daily smoking among Swedes aged 16–84 was 5.4% in 2024, while daily snus use stood at 15.7%. Among 16- to 29-year-olds, daily smoking had fallen to just 2%.

Nevertheless, the international pattern provides strong evidence that consumers can substitute lower-risk nicotine products for cigarettes when those alternatives are accessible and acceptable. The scale of this transition is now difficult to dismiss. GSTHR’s peer-reviewed estimates indicate that approximately 129 million people vaped in 2025, while around 78 million used heated tobacco products in 2024, in addition to tens of millions using snus and nicotine pouches.

The evidence for vaping as a cessation tool is undeniable

Vaping is not risk-free, but the relevant public-health comparison for an adult smoker is generally not vaping versus doing nothing. It is vaping versus continuing to inhale cigarette smoke. Reliable evidence increasingly supports that distinction. The latest Cochrane living systematic review included 104 studies involving 30,366 adults who smoke and found that nicotine e-cigarettes help more people quit smoking for at least six months than nicotine replacement therapy. For every 100 people using nicotine e-cigarettes, approximately eight to 11 may stop smoking, compared with around six using NRT.

Recent research is also adding to the evidence on toxicant exposure. A randomised clinical trial published in JAMA Network Open found that adults who switched from cigarettes to a nicotine pod-based e-cigarette experienced reductions in certain biomarkers associated with cigarette smoke exposure. The study concluded that effective nicotine delivery may help facilitate both smoking cessation and reductions in toxicant exposure.

Prohibition has never decreased demand

One of the report’s most important warnings concerns the growing disconnect between consumer behaviour and government policy. GSTHR found that restrictive measures targeting safer nicotine products vastly outnumbered policies expanding access during the period examined. By March 2026, it estimated that 109 countries—around one-third of the world’s population—had banned safer nicotine products outright.

But prohibition does not necessarily eliminate demand. The US provides a useful illustration. Research published in the American Journal of Preventive Medicine found that the amount of nicotine contained in e-cigarettes sold monthly increased by 249.2% between February 2020 and June 2024, while standardised unit sales rose by only 34.7%. Disposable products accounted for much of this expansion.

The lesson is that consumer demand for nicotine alternatives remains substantial even when regulators attempt to restrict particular products. Excessively restrictive policies can therefore create opportunities for illicit suppliers while removing regulated products from legitimate businesses.

The inequality problem

Perhaps the biggest missed opportunity lies in low- and middle-income countries, where most of the world’s smokers live. GSTHR reports that safer nicotine products remain disproportionately accessible in high-income countries. In many lower-income markets, cigarettes remain the cheapest nicotine product, while alternatives carry a significant price premium.

That creates a particularly troubling policy contradiction. The people who could potentially gain the most from switching away from combustible tobacco are often those facing the greatest financial barriers to doing so. Tobacco harm reduction should therefore not simply mean allowing safer products to exist. They need to be affordable, appropriately regulated and realistically accessible to adult smokers.

Change is already underway. Will lawmakers choose to keep up?

Smoking remains one of the world’s largest preventable causes of death, responsible for millions of deaths every year. The economic consequences are similarly enormous, including healthcare expenditure, lost productivity and premature mortality. Yet tobacco control policy frequently focuses on reducing nicotine use rather than prioritising the elimination of the most dangerous form of nicotine consumption: combustible tobacco. Emerging evidence suggests these objectives should not be confused.

The 2026 GSTHR report describes a world in which consumers are already conducting a vast, largely uncoordinated experiment in substitution. Around 200 million people have chosen safer nicotine products, while smoking continues to decline in many countries where those products are available. For policymakers, the opportunity is clear. Rather than treating every nicotine product as equivalent, regulation can distinguish between levels of risk, protect young people and non-smokers, maintain product standards and give adult smokers credible alternatives to cigarettes.

The Recent Motions Across the Globe Keeping Cigarettes on Top and Safer Alternatives Underground

Source link

Europe’s Tobacco-Free Ambition is on a Direct Collision With Its Crackdown on Safer Nicotine

admin — Sat, 15 Aug 2026 07:43:37 +0000

A series of formal objections to proposed nicotine restrictions in Ireland and Poland is exposing the growing fault line in European tobacco policy. The dispute arrives at a pivotal moment. The European Commission is preparing to modernise its tobacco-control framework, while individual governments are advancing restrictions on vaping flavours, nicotine pouches, packaging and newer nicotine products.

Harm reduction advocates fear these policies could make cigarettes comparatively more attractive just as Europe is struggling to meet its 2040 tobacco-free target. Recent interventions by EU member states suggest those concerns are no longer confined to consumers and advocacy organisations.

EU member states challenge proposed bans in Ireland and Poland

Ireland’s Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026 proposes extensive controls over vaping products, including packaging, presentation, advertising and retail displays. Among its most controversial elements are restrictions that would effectively limit vape flavour descriptions to “Tobacco” and “Unflavoured.”

The intervention matters because EU rules allow member states to pursue public health protections, but national technical regulations that could disrupt the single market must be justified.

Greece and Italy have submitted detailed opinions through the European Commission’s Technical Regulation Information System (TRIS), extending the standstill period and requiring Ireland to address questions surrounding the necessity and proportionality of its approach.

The intervention matters because EU rules allow member states to pursue public health protections, but national technical regulations that could disrupt the single market must be justified. Smoke Free Sweden leader Dr Delon Human argues that Ireland should use the delay to distinguish between measures designed to prevent youth access and restrictions that reduce the attractiveness of vaping for adults who smoke.

A similar dispute is unfolding in Poland, where the government proposes banning most flavours in nicotine products, prohibiting disposable vapes and bringing some newer nicotine products within pharmaceutical regulation. Sweden, joined by Romania, Slovakia and Greece, has challenged elements of the proposal through TRIS, extending Poland’s standstill period until November.

This reflects an important principle of EU regulation: when a government effectively removes much of a lawful product category, it should demonstrate why less restrictive alternatives—such as age restrictions, retailer licensing, advertising controls, product standards and nicotine limits—would be insufficient.

We have all the data needed to validate the need for flavours

This is particularly relevant to nicotine pouches. Tobacco-free pouches deliver nicotine without combustion, inhalation or tobacco leaf. Requiring such products to resemble tobacco in flavour could be counterproductive for former smokers deliberately trying to distance themselves from cigarettes. Poland undoubtedly has legitimate reasons to prevent youth nicotine use. The question is whether eliminating adult-oriented alternatives represents the most effective response.

Studies have consistently shown that smokers may initially choose familiar tobacco flavours but subsequently prefer fruit, menthol or other varieties as they distance themselves from cigarettes. Removing these options, argue experts, could weaken one of vaping’s advantages as a substitute for smoking.

A longitudinal study by Yale researchers found that adults who began using flavoured vapes were more likely subsequently to quit smoking than those using tobacco-flavoured products, although the observational design cannot establish that flavours themselves caused cessation.

More recent US research has raised another concern: substitution. Yale researchers examining flavour restrictions across multiple jurisdictions found that reductions in legal e-cigarette sales were accompanied by increased cigarette purchases. Their estimates indicated 15 additional cigarettes were sold for every 0.7ml of vape liquid no longer purchased following restrictions.

This does not prove every European flavour restriction will produce the same result. It does, however, demonstrate why policymakers should examine unintended consequences rather than treating falling legal vape sales as synonymous with improved health

Sweden inevitably features prominently in this debate because its experience challenges the assumption that widespread availability of smoke-free nicotine must translate into high smoking prevalence. Smoke Free Sweden currently cites a daily smoking rate of 5.3% and substantially lower tobacco-related mortality than the European average.

Europe wants a tobacco-free Generation. So why restrict alternatives to cigarettes?

The European Commission’s own Europe’s Beating Cancer Plan provides an important reference point. Its formal objective is a “Tobacco-Free Generation”, defined as reducing tobacco use to below 5% of the population by 2040.

That wording matters. A tobacco-free target is not inherently the same thing as a nicotine-free target. Vapes and nicotine pouches can contain nicotine without containing tobacco, while nicotine replacement products have delivered the same addictive substance therapeutically for decades.

The public-health rationale for distinguishing products is straightforward: cigarette smoking is uniquely hazardous because combustion produces a complex mixture of toxicants and carcinogens. This does not mean in any way that non-smokers—particularly minors—should start using nicotine. It means that the risk faced by an adult switching completely from cigarettes to a non-combustible alternative is fundamentally different from the risk of continuing to inhale cigarette smoke.

Moreover, a 2025 Cochrane living systematic review highlighted a difficult policy paradox. Excessive restrictions on the regulated market may not eliminate demand. They can instead encourage consumers to seek illicit products—the very products for which quality, ingredients, nicotine concentrations and age controls are hardest to guarantee.

Tobacco-free or nicotine-free? When will they acknowledge the difference

None of this requires Europe to ignore youth vaping. Governments have legitimate reasons to enforce minimum-age laws, restrict child-oriented branding, control advertising, establish manufacturing standards and prevent products resembling toys or confectionery from being marketed to minors.

But regulating presentation is different from eliminating the characteristics that make smoke-free alternatives acceptable to adults. The most effective framework would recognise a continuum of nicotine-related risk. Cigarettes should face the strongest regulatory and fiscal pressure because they cause the greatest harm. Lower-risk products should be tightly regulated for quality and youth access while remaining sufficiently affordable, accessible and appealing to compete with smoking. Ireland and Poland now have an opportunity to reconsider whether their proposals achieve that balance.

The wider significance extends far beyond either country. As Brussels prepares for its next generation of tobacco and nicotine regulation, Europe must decide whether its ultimate objective is to eliminate cigarette smoking and the extraordinary disease burden caused by combustion—or gradually broaden tobacco control into a campaign against nicotine use itself. Those are not necessarily the same public-health goal.

If Europe genuinely intends to reduce tobacco use below 5% by 2040, Sweden provides at least one lesson worth investigating rather than dismissing: people do not necessarily have to stop using nicotine before they stop smoking. Regulation that protects young people while encouraging adults away from cigarettes could accelerate Europe’s progress. Regulation that makes safer substitutes progressively less attractive, meanwhile, risks protecting the product policymakers should be trying hardest to eliminate—the combustible cigarette.

Source link